Literature DB >> 18609727

Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies.

Stacy A Davis, Robert R Johnson, John W Pendleton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18609727

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  5 in total

Review 1.  New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.

Authors:  Takumi Matsumoto; Ichiro Nakamura; Ayumi Miura; Gen Momoyama; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2012-11-14       Impact factor: 2.980

Review 2.  CNS Demyelination with TNF-α Blockers.

Authors:  Elissavet Kemanetzoglou; Elisabeth Andreadou
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

3.  PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.

Authors:  Sinah Engel; Felix Luessi; Aneka Mueller; Rudolf E Schopf; Frauke Zipp; Stefan Bittner
Journal:  Ther Adv Neurol Disord       Date:  2020-01-02       Impact factor: 6.570

Review 4.  Drug-related immune-mediated myelopathies.

Authors:  David Gritsch; Cristina Valencia-Sanchez
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

5.  Identification of autoimmune gene signatures in autism.

Authors:  J-Y Jung; I S Kohane; D P Wall
Journal:  Transl Psychiatry       Date:  2011-12-13       Impact factor: 6.222
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.